Oral JBI-778 for brain metastases and recurrent brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial tests an oral medication (JBI-778) for people with brain metastases or certain brain tumors that have not responded to standard treatment. It aims to see if the drug is safe and if it can help shrink or stabilize the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have brain metastases (cancer that has spread to the brain), leptomeningeal disease (cancer in the fluid around the brain or spinal cord), or a recurrent high-grade glioma (a type of brain tumor).
- Your cancer must have progressed or not responded to previous standard treatments.
- You must be in reasonably good health, with adequate organ function (liver, kidneys, blood counts).
- You must be able to swallow oral medication.
- You must not have certain heart conditions, active infections (like HIV, hepatitis B or C), or have taken strong medications that interact with this drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called GSK5764227 (a B7-H3 targeted antibody-drug conjugate) in people whose glioblastoma has come back after standard treatment, or who have brain metastases that need surgery. The goal is to see if the drug can help shrink or control the tumor.
This trial tests a new oral medication, JBI-778, in patients with certain types of lung cancer, brain tumors, or salivary gland cancer. The drug is designed to target specific genetic changes in these tumors, and the study aims to assess its safety and effectiveness.
This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.
This trial tests how well different doses of a new drug, BI 764532, are tolerated by people with a specific type of brain tumor (glioma) that has not responded to standard treatments. The drug targets a protein on the tumor cells, which may help slow tumor growth.
This trial tests an oral drug called NBM-BMX for people with advanced solid tumors that have not responded to other treatments, or for people with newly diagnosed glioblastoma (a type of brain cancer). The study aims to see if the drug is safe and effective.
This trial tests an experimental cell therapy (MT027) for people with high-grade brain tumors that have come back or stopped responding to treatment. It targets a protein called B7-H3 found on tumor cells, aiming to attack the cancer.
Hear when a new Brain Metastases From Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.